Spine Biologics Market Research, 2033
The global spine biologics market size was valued at $3.1 billion in 2023, and is projected to reach $5.2 billion by 2033, growing at a CAGR of 5.4% from 2024 to 2033. The spine biologics market is expected to register significant growth owing to rising prevalence of spinal disorders and the increasing aging population. Furthermore, increasing awareness and acceptance of minimally invasive surgical procedures, along with favorable reimbursement policies, are further propelling the market.
Market Introduction and Definition
Spine biologics are specialized biological materials used to promote healing, enhance spinal fusion, and treat various spinal disorders. Spinal biologics include substances such as bone grafts, growth factors, and stem cells, which are designed to support the body's natural healing processes. Bone grafts can be autografts, taken from the patient’s own body, or allografts, sourced from a donor, and are used to provide a scaffold for new bone growth. Growth factors, like bone morphogenetic proteins (BMPs) , stimulate the cells involved in bone repair and regeneration. Stem cells, which have the ability to differentiate into various cell types, can be harnessed to regenerate damaged spinal tissues. The use of spine biologics is particularly prevalent in spinal fusion surgeries, where the goal is to join two or more vertebrae to eliminate pain caused by abnormal motion. Advances in biotechnology have significantly enhanced the effectiveness and safety of these materials, making them a crucial component in modern spine surgery and rehabilitation.
Key Takeaways
- The spine biologics market share study covers 20 countries. The research includes a segment analysis of each country in terms of value for the projected period.
- More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major spine biologic industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
- The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives.
Key Market Dynamics
According to the spine biologics market analysis, key factors driving the market growth are rise in geriatric population, surge on prevalence of spinal disorders, and technological advancement. According to an article by World Health Organization, in 2025 the population over 60 years will be around 22% of total population. As the population ages, the prevalence of age-related spinal disorders such as degenerative disc disease, spinal stenosis, and osteoporotic fractures increases. Older adults are more susceptible to these conditions due to the natural wear and tear of the spine, decreased bone density, and other physiological changes associated with aging. Consequently, there is a growing demand for advanced medical treatments and interventions to address these spinal issues and improve the quality of life for elderly patients. Spine biologics, which include bone graft substitutes, growth factors, and cell-based therapies, offer promising solutions for enhancing spinal fusion, accelerating healing, and reducing recovery times. Thus, the rise in the geriatric population is expected to drive the spine biologics market growth.
Moreover, according to spine biologics market forecast analysis, technological advancement in spine biologics is expected to contribute significantly in the growth of the market. Innovations in biotechnology, such as advanced gene editing techniques and tissue engineering, have led to the development of more effective and safer biologic materials. For instance, in November 2023, Spinal Elements announced the full commercial launch of their Ventana 3D-Printed Interbody Portfolio. The Ventana C Anterior Cervical Interbody System, Ventana P/T Posterior Lumbar Interbody System and Ventana L Lateral Lumbar Interbody System. The Ventana portfolio was developed by spinal elements and is the newest innovation in its MIS Ultra platform of products and procedural solutions. As a result, the technological advancement has led to development of safer and more biocompatible products and is expected increased adoption of the spine biologics products such as spinal allografts, bone graft substitutes. Thus, the technological advancement in the spine biologics is expected to drive the growth of the spine biologics market size.
Spinal Cord Injuries, by Cause
Between 2015 and 2023, spinal cord injuries (SCIs) in U.S. occurred due to a variety of causes, with vehicular incidents being the most significant contributor, accounting for 37.5% of cases. Falls were the second most common cause, responsible for 31.7% of spinal cord injuries during this period. Acts of violence, including gunshot wounds and assaults, made up 15.4% of the injuries. Sports-related activities contributed to 8% of spinal cord injuries. Medical and surgical complications were responsible for 3.7% of the injuries, underscoring potential risks within clinical settings. Lastly, other causes comprised 3.8% of spinal cord injuries.
According to spine biologics market trends analysis, increasing incidence of spinal cord injuries (SCIs) is significantly driving the growth of the market. Spinal cord injuries, which can result from trauma such as car accidents, falls, sports injuries, and violence, have been on the rise globally. These injuries often lead to severe disabilities, requiring extensive medical intervention and long-term care. As a result, there is a growing demand for advanced medical treatments that can improve outcomes for patients with spinal cord injuries. Spine biologics, which include growth factors, stem cells, and other biological materials, play a crucial role in enhancing the body's natural healing processes, reducing inflammation, and promoting the regeneration of damaged tissues. The surge in spinal cord injuries cases has spurred research and development in this field, leading to innovations and advancements in biologic products tailored for spinal health. Moreover, the aging population, which is more susceptible to degenerative spinal conditions, further amplifies the need for effective biologic therapies.
Market Segmentation
The spine biologic industry is segmented into by product, end user, and region. By product, the market is divided into spinal allografts, bone graft substitutes, cell-based matrix. By end users, the market is divided into hospitals, outpatient facilities. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA
Regional/Country Market Outlook
North America dominated the spine biologics market share in 2023, owing to high prevalence of diabetes-related amputations and robust healthcare system and increasing adoption of minimally invasive surgeries, and strong presence of major key players. Regulatory bodies like the U.S. Food and Drug Administration (FDA) provide a structured pathway for the approval and commercialization of spine biologic products. While the approval process is rigorous, it ensures that only safe and effective products reach the market, thereby building trust among healthcare providers and patients.However, according to spine biologics market opportunity analysis, Asia-Pacific region is witnessing rapid growth propelled by increasing healthcare expenditure, rising geriatric population, and developing healthcare infrastructure.
- In an article published in 2023 by United Nations Population Fund, in India there are around 153 million elderly population. As people age, they become more prone to degenerative spine conditions such as osteoarthritis, degenerative disc disease, spinal stenosis, and vertebral fractures. These conditions can cause chronic back pain, loss of mobility, and decreased quality of life. The growing geriatric population means an increasing number of individuals affected by these spine disorders, driving the demand for spine biologics to address their treatment needs.
- According to 2021 article by Australian Institute of Health and Welfare, Spinal injury contributed to 6% of fall-related injury and 12% of transport-related injury. Spinal injuries can cause severe pain, loss of sensation, paralysis, and other debilitating symptoms, significantly impacting the quality of life of affected individuals. Spine biologics offer the potential to enhance tissue repair, promote spinal fusion, and improve neurological recovery, thereby providing improved treatment outcomes in patients with spinal injuries.
- In a 2024 article published by National Library of Medicine, it was reported that motor vehicular crashes causes 38% of new injuries spinal chord injuries each year. As the incidence of spinal trauma rises, there is a growing need for effective treatments. Research and innovation in spine biologics have led to the development of novel therapeutic approaches tailored specifically for spinal cord injuries. Thus, the rise in the incidence of the spinal chord injuries is expected to drive the growth of the market
Industry Trends
- According to World Health Organization, in 2021, around 15.4 million people were living with spinal cord injury. Since the spine biologic products such as cell-based matrix are majorly used to treat spinal chord injury, the rise in the spinal chord injury is expected to drive the demand for the spine biologic.
- In a 2023 article published by National Library of Medicine, it was reported that 80% of Americans suffers from low back pain during their lifetime. Lower back pain can be effectively treated using bone grafts such as autograft, allograft and synthetic bone graft. Thus, the rise in the patient suffering from lower back pain is expected to drive the demand for the spinal biologics products such as bone graft.
Competitive Landscape
The major players operating in the Spine biologic market include Stryker, NuVasive, Inc., Orthofix, Johnson & Johnson, Exactech, Inc., Zimmer Biomet. Arthrex, Inc., Medtronic Plc, Organogenesis Inc., and Kuros Biosciences. Other players in Spine biologic market includes Globus Medical Inc, RTI Surgical Inc, and SeaSpine.
Recent Key Strategies and Developments
- In October 2023, Orthofix Medical Inc., a major provider of spine and orthopedics products, announced the full commercial launch and 510k clearance of an advanced bioactive synthetic graft, OsteoCove, for use in orthopedic and spine procedures. The product is available in both strip and putty configurations.
- In July 2023, Cerapedics Inc., a major provider of bone grafts, expanded its headquarters in the Denver metro area. This expansion is expected to support the company’s portfolio of various products, including i-FACTOR bone grafts that can be used for cervical spinal fusion.
- In April 2023, PUR Biologics, a subsidiary of HippoFi, Inc., introduced a bioactive moldable synthetic PURcore. This product is useful for spinal surgeries.
Key Sources Referred
- World Health Organization
- Government of UK
- Center of Disease Control and Prevention.
- National Library of Medicine
- United Nations Population Fund
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the spine biologics market identify the prevailing spine biologics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the spine biologics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global spine biologics market trends, key players, market segments, application areas, and market growth strategies.
Spine Biologics Market, by Product Report Highlights
| Aspects | Details |
 Market Size By 2033 | USD 5.2 Billion |
 Growth Rate | CAGR of 5.4% |
 Forecast period | 2024 - 2033 |
 Report Pages | 280 |
 By Product |
|
 By End User |
|
 By Region |
|
 Key Market Players | Organogenesis Inc, Johnson & Johnson, Zimmer Biomet Holding, Inc., Medtronic plc, orthofix, NuVasive, Inc., Stryker Corporation, Kuros Biosciences, Exactech, Inc, Arthrex, Inc. |
Analyst Review
Spinal disorders such as spinal stenosis, spondylolisthesis, and scoliosis constitute a major proportion of health and economic burden, hence usage of effective spine biologics during spine surgery becomes a vital need for the treatment of the spinal disorders. To alleviate the aforementioned spine-related disorders and improve patient’s quality of life, spinal surgery is emerging as an ideal treatment option. Thus, rise in demand for spine surgery consequently drives the growth of spine biologics market, as biologics are widely adopted to promote fusion healing, which pedicle screws and rods are unable to provide.
Increase in incidences of spine-related disorders such as stenosis has led to the increase in the adoption of the spinal biologics. In addition, elimination of the need to harvest bone from the patient’s body in a secondary procedure, stimulation of the process of bone growth in spinal fusion surgery, shorter operating times, and reduced hospital stays fuel the growth of the market globally.
Advent of spine surgery treatment is one of the major factors that boosts the market growth. For instance, most of the spine surgeons these days prefer minimal invasive surgical techniques for a wide range of spine fusion procedures, which further use spine biologics. This is attributed to minor complications associated with the procedure such as reduced length of hospital stays and less bleeding.
Geographically, Asia-Pacific offers lucrative growth opportunity for the market due to growth in healthcare expenditure, increase in geriatric population, and rise in incidence of spine impairments. Thus, emerging economies (such as China & India) possess high potential for the market growth in spine biologics.
The forecast period for Spine Biologics Market is 2024-2033.
The global spine biologics market size was valued at $3.1 billion in 2023
The market value of Spine Biologics Market is projected to reach $5.2 Billion by 2033
Major key players that operate in the Spine Biologics Market Stryker, NuVasive, Inc., Orthofix, Johnson & Johnson, Exactech, Inc., and Zimmer Biomet
The base year is 2023 in Spine Biologics Market.
The Spine Biologics Market growth is driven by surge prevalence of spinal disorders, increasing aging population, and increasing awareness and acceptance of minimally invasive surgical procedures.
Loading Table Of Content...
